Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14057787 | 0.91 | HPGD (0.69) | HPGDSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL15101544 | 0.90 | HPGD (0.64) | HPGDTP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL29631038 | 0.90 | HPGD (0.64) | HPGDTP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL1494880 | 0.85 | TP53 (0.67) | HPGDTP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL19002579 | 0.85 | HPGD (0.58) | HPGDTP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL12682923 | 0.82 | HPGD (0.69) | HPGDSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL1495244 | 0.81 | HPGD (0.70) | HPGDTP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL3182062 | 0.81 | TP53 (0.55) | HPGDTP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL10066942 | 0.79 | TP53 (0.57) | HPGDTP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL21490265 | 0.78 | HPGD (0.67) | HPGDSMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | HPGD 365/4885TP53 124/4885SMN1; SMN2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.